1Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST- segment elevation[J].N Engl J Meal,2001,345(7): 494-502.
2Gurbel PA,Bliden KP, Guyer K,et al.Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST- STENTING Study[J].J Am Coil Cardiol,2005,46 (10): 1820-1826.
3Kazui M,Nishiyar,Ishizukar,et al .Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J].Drug Metab Dispos,2010,38(1):92-99.
4Sturr NK,Gough A,Stevenson K,et al.Isolation of human cytoehrome p450 cDNA for the study of linkage in human disease[J].Cytosenet Cell Genet, 1987,46(6):698.
5Coutts RT, Unchuk LJ.Polymorphic cytochromes p450 and drugs used in psychiatry[J].Cell Mol "Neurobiol, 1999,19(3):325-354.
7Xie HG,Kim RB,Wood AJ,et al.Molecular basis of ethnic diffe- rences in drug disposition and response[J].Armu Rev Pharmacol Toxicol,2001,41:815-850.
8Sibbing D,Koch W, Gebhard D,et al.Cytochrome 2C19* 17 allelic variant,platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation,2010,121 (4):512-518.
9Hulot JS,Bura A,Villard E,et al.Cytochrome P450 2C19 loss-of- function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J].Blood,2006, 108(7):2244- 2247.
10Mega JL,Close SL,Wiviott SD,et al.Cytochrome P450polymor- phisms and response to clopidogrel[J].N Engl J Meal,2009,360(4): 354-362.
7Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocarc- tion with ST-segment elevation [ J ]. N Engl J Med, 2005, 352(12) :1179.
8Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug- eluting stent thrombosis [ J ]. J Am Coil Cardiol, 2007,49 (24) :2312.
9Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmaeokinetic and pharmacodyna- mic responses to clopidogrel but not prasugrel in aspirin- treated patients with coronary artery disease[ J]. Eur Heart J,2009,30 ( 14 ) : 1744.
10de Morals SM,Wilkinson GR, BlaisdelⅡ, et al. The major genetic defect responsible for the polymorphism of S-me- phenytoin metabolism in humans[J], J Biol Chem, 1994, 269(22) :15419.
